<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

CAR-T vs. bispecifics for lymphoma: Using the evidence to sequence treatments

Default sub title

minute read

by Healio | January 4, 2024
placeholder

Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.

Topics: Press Coverage